The U.S. Food and Drug Administration (FDA) granted fast track designation to Vistagen (NASDAQ:VTGN) PH10 nasal spray to treat major depressive disorder (MDD) in adults.
The company said the FDA's decision was backed by results of Vistagen's nonclinical studies and three prior clinical studies of PH10, including a phase 2a trial in MDD.
Last week, Vistagen received the FDA's greenlight to proceed with an early-stage trial of PH10.
